Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | MSDA test classifies relapsing MS patients based on steroid response and disease activity status

Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, describes a study that evaluated the utility of the multivariate proteomic multiple sclerosis disease activity (MSDA) test in identifying serum biomarkers predictive of steroid response. The study aimed to assess the association of individual proteins, disease activity (DA) score, and disease pathways scores with relapsing-remitting multiple sclerosis (RRMS) patients in stable disease phase, with steroid responsive or steroid resistant phase as well as gadolinium-enhancing (Gd+) lesions status. Results showed that the DA score, the pathway scores, and individual biomarkers were significantly associated with the steroid responsiveness categories. Additionally, the DA and the pathway scores were significantly associated with Gd+ status. These findings underline the utility of the MSDA test and provide further evidence of its replication in independent cohorts. This interview took place at the ECTRIMS Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ferhan Qureshi is an employee of Octave Bioscience.